Sernova Corp T.SVA

Imagine

[markeg]

Imagine if at the upcoming conference Dr. toleikis says that thier test patient was no longer needing insulin shots.  Wouldn't that be wild...

[BioTeck]

It would but also very unlikely. Even a small reduction would be a significant accomplishment at this stage as they are still experimenting with dosing.

[Redbaron2211]

They have been honing islet dosing for over a year now it's very possible a patient is close or totally off insulin.

[stockhunter1]

https://www.podbean.com/media/share/pb-adq3y-f52157?utm_campaign=u_share_ep&utm_medium=dlink&utm_source=u_share . Some folks have clearly listened [ well worth the time ]  to what the good Dr. Tolekis says in this interview...pay close attention to the last 2 mins, it does set a tempo of what will be discussed by him and Dr. Witkowski in the very near term in interviews

[markeg]

Imagine if he said for over 9 months no insulin was required by this test subject. This is all hypothetical of course

[BioTeck]

It is also possible that they aren't. In fact, it's much  more likely they are not. Not saying impossible, just very unlikely based on the previous results released.

[Redbaron2211]

We will find out soon enough. I'm not expecting it but I wouldn't be surprised is all I'm saying. Regardless of where dosing is we still have plenty of upside with or without.

[Redbaron2211]

Here is a refresh of the latest efficacy findings. Note these are trends not individual findings. The trend is islets are surving and producing insulin. In this trend some will be closer to insulin independence then others. It's possible one or more patients are very close to or at insulin independence. If they are we probably won't hear about it until there is more data but its a

[Redbaron2211]

Sorry Jwall if your still reading that is hard to read..  I will try to do better see below; Highlighting some of the trial efficacy findings with focus on clinical benefits to the T1D patients, the following trends have also been observed. EFFICACY (Secondary Endpoint): - Ongoing detection of bloodstream levels of C-peptide in treated patients (proof that cells in the Cell Pouch are